Following MMR immunohistochemistry and MLH1 promoter methylation analysis, all cases with loss of protein expression of PMS2 only, MSH2 and/or MSH6, or MLH1 without MLH1 promoter hypermethylation need to be triaged as potential Lynch syndrome-associated endometrial cancer. This evidence concerns the gene MLH1 and Lynch syndrome.